MicroRNA let-7: An emerging next-generation cancer therapeutic

Current Oncology

Volumn 17, Issue 1, 2010, Pages 70-80

  Barh, D ^a   Malhotra, R ^b   Ravi, B ^c   Sindhurani, P ^a  

^a Institute of Integrative Omics and Applied Biotechnology   (India)

^b BANGALORE UNIVERSITY   (India)

^c CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

Cancer therapy; Future medicine; Let 7; Let 7 regulation; MicroRNA

Indexed keywords

ADENOVIRUS VECTOR; ESTROGEN RECEPTOR; HIGH MOBILITY GROUP A2 PROTEIN; LENTIVIRUS VECTOR; MICRORNA; MICRORNA LET 7; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL DIFFERENTIATION; DEREGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE CONTROL; GENE TARGETING; HUMAN; LUNG CANCER; NONHUMAN; ONCOGENE RAS; PROTEIN EXPRESSION; REVIEW;

EID: 75849151945     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i1.356     Document Type: Review

References (110)

1. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAS: are the answers in sight? Nat Rev Genet 2008;9:102-14.
2. Ivey KN, Muth A, Arnold J, et al. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell 2008;2:219-29.
3. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006;38:228-33.
4. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007;129:303-17.
5. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, Regazzi R. MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 2006;281:26932-42.
6. Lukiw WJ, Pogue AI. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. J Inorg Biochem 2007;101:1265-9.
7. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAS by p53 revealed by massively parallel sequencing: MIR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007;6:1586-93.
8. Kumamoto K, Spillare EA, Fujita K, et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate MIR-34a, MIR-34b, and MIR-34c expression, and induce senescence. Cancer Res 2008;68:3193-203.
9. Maes OC, An J, Sarojini H, Wang E. Murine microRNAS implicated in liver functions and aging process. Mech Ageing Dev 2008;129:534-41.
10. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAS modulate hematopoietic lineage differentiation. Science 2004;303:83-6.
11. Rodriguez A, Vigorito E, Clare S, et al. Requirement of Bic/microRNA-155 for normal immune function. Science 2007;316:608-11.
12. Hébert SS, Horré K, Nicolaï L, et al. Loss of microRNA cluster MIR -29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression. Proc Natl Acad Sci U S A 2008;105:6415-20.
13. Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA MIR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008;28:1213-23.
14. Wang G, van der Walt JM, Mayhew G, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 2008;82:283-9.
15. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAS play an essential role in the development of cardiac hypertrophy. Circ Res 2007;100:416-24.
16. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005;436:214-20.
17. Pezzolesi MG, Platzer P, Waite KA, Eng C. Differential expression of PTEN-targeting microRNAS MIR -19a and MIR-21 in Cowden syndrome. Am J Hum Genet 2008;82:1141-9.
18. Kuhn DE, Nuovo GJ, Martin MM, et al. Human chromosome 21-derived miRNAS are overexpressed in Down syndrome brains and hearts. Biochem Biophys Res Commun 2008;370:473-7.
19. Blenkiron C, Miska EA. miRNAS in cancer: approaches, aetiology, diagnostics and therapy. Human Mol Genet 2007;16:R106-13.
20. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-6.
21. Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAS that control C. elegans developmental timing. Cell 2001;6:23-34.
22. Abbott AL, Alvarez-Saavedra E, Miska EA, et al. The let-7 microRNA family members MIR-48, MIR-84, and MIR-241 function together to regulate developmental timing in Caenorhabditis elegans. Dev Cell 2005;9:403-14.
23. Li M, Jones-Rhoades MW, Lau NC, Bartel DP, Rougvie AE. Regulatory mutations of MIR-48, a C. elegans let-7 family microRNA, cause developmental timing defects. Dev Cell 2005;9:415-22.
24. Grosshans H, Johnson T, Reinert KL, Gerstein M, Slack FJ. The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Dev Cell 2005;8:321-30.
25. Frasch M. A matter of timing: microRNA-controlled temporal identities in worms and flies. Genes Dev 2008;22:1572-6.
26. Caygill EE, Johnston LA. Temporal regulation of metamorphic processes in Drosophila by the let-7 and MIR-125 heterochronic microRNAS. Curr Biol 2008;18:943-50.
27. Sokol NS, Xu P, Jan YN, Ambros V. Drosophila let-7 microRNA is required for remodeling of the neuromusculature during metamorphosis. Genes Dev 2008;22:1591-6.
28. Wienholds E, Kloosterman WP, Miska E, et al. microRNA expression in zebrafish embryonic development. Science 2005;309:310-11.
29. Tsonis PA, Call MK, Grogg MW, et al. microRNAS and regeneration: let-7 members as potential regulators of dedifferentiation in lens and inner ear hair cell regeneration of the adult newt. Biochem Biophys Res Commun 2007;362:940-5.
30. Wulczyn FG, Smirnova L, Rybak A, et al. Post-transcriptional regulation of the let-7 microRNA during neural cell specification. FASEB J 2006;21:415-26.
31. Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R, Hannon GJ. A role for microRNAS in maintenance of mouse mammary epithelial progenitor cells. Genes Dev 2007;21:3238-43.
32. Bar M, Wyman SK, Fritz BR, et al. microRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries. Stem Cells 2008;26:2496-505.
33. Mi S, Lu J, Sun M, et al. microRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007;104:19971-6.
34. Nam S, Kim B, Shin S, Lee S. MIRGator: an integrated system for functional annotation of microRNAS. Nucleic Acids Res 2008;36:D159-64.
35. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007;67:11612-20.
36. Yu F, Yao H, Zhu P, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23.
37. Inamura K, Togashi Y, Nomura K, et al. Let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer 2007;58:392-6.
38. Sampson VB, Rong NH, Han J, et al. microRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67:9762-70.
39. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAS in colorectal neoplasia. Mol Cancer Res 2003;1:882-91.
40. Akao Y, Nakagawa Y, Naoe T. Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006;29:903-6.
41. Fang WJ, Lin CZ, Zhang HH, Qian J, Zhong L, Xu N. Detection of let-7a microRNA by real-time PCR in colorectal cancer: a single-centre experience from China. J Int Med Res 2007;35:716-23.
42. Zhang HH, Wang XJ, Li GX, Yang E, Yang NM. Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol 2007;13:2883-8.
43. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 2008;14:2334-40.
44. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007;67:7713-22.
45. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAS in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
46. Johnson SM, Grosshans H, Shingara J, et al. Ras is regulated by the let-7 microRNA family. Cell 2005;120:635-47.
47. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. microRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008;18:549-57.
48. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007;67:10117-22.
49. Jérôme T, Laurie P, Louis B, Pierre C. Enjoy the silence: the story of let-7 microRNA and cancer. Curr Genomics 2007;8:229-33.
50. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005;33:5394-403.
51. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008;105:3945-50.
52. Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A 2008;105:3903-8.
53. Okamura K, Phillips MD, Tyler DM, Duan H, Chou YT, Lai EC. The regulatory activity of microRNA* species has substantial influence on microRNA and 3′ UTR evolution. Nat Struct Mol Biol 2008;15:354-63.
54. Richards M, Tan SP, Tan JH, Chan WK, Bongso A. The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 2004;22:51-64.
55. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin-28. Science 2008;320:97-100.
56. Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. Lin28 mediates the terminal uridylation of let-7 precursor microRNA. Mol Cell 2008;32:276-84.
57. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the let-7 precursor loop mediates regulated microRNA processing. RNA 2008;14:1539-49.
58. Piskounova E, Viswanathan SR, Janas M, et al. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem 2008;283:21310-14.
59. Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 2008;10:987-93.
60. Peter ME. Let-7 and MIR-200 microRNAS: guardians against pluripotency and cancer progression. Cell Cycle 2009;8:843-52.
61. Arf expression. Cell 2008;135:227-39.
62. Lengner CJ, Camargo FD, Hochedlinger K, et al. OCT4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 2007;1:403-15.
63. Droge P, Davey CA. Do cells let-7 determine stemness? Cell Stem Cell 2008;2:8-9.
64. Boyerinas B, Park SM, Shomron N, et al. Identification of let-7-regulated oncofetal genes. Cancer Res 2008;68:2587-91.
65. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007;58:267-84.
66. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675-99.
67. Park SM, Shell S, Radjabi AR, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007;6:2585-90.
68. Giannini G, Kim CJ, Di Marcotullio L, et al. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. Br J Cancer 2000;83:1503-9.
69. Chiappetta G, Bandiera A, Berlingieri MT, et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995;10:1307-14.
70. Abe N, Watanabe T, Suzuki Y, et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 2003;89:2104-9.
71. Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006;209:206-12.
72. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19:1262-70.
73. Hansen TV, Hammer NA, Nielsen J, et al. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol 2004;24:4448-64.
74. Yisraeli JK. VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell 2005;97:87-96.
75. Kiel MJ, Iwashita T, Yilmaz OH, Morrison SJ. Spatial differences in hematopoiesis but not in stem cells indicate a lack of regional patterning in definitive hematopoietic stem cells. Dev Biol 2005;283:29-39.
76. Sun Y, Li H, Liu Y, Mattson MP, Rao MS, Zhan M. Evolutionarily conserved transcriptional co-expression guiding embryonic stem cell differentiation. PLoS ONE 2008;3:3406.
77. Knoepfler PS. Why Myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell 2008;2:18-21.
78. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor Hmgi-C. Nature 1995;376:771-4.
79. Ioannidis P, Mahaira LG, Perez SA, et al. CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects C-myc and IGF-II expression in MCF-7 cancer cells. J Biol Chem 2005;280:20086-93.
80. Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. PPARA regulates an miRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 2007;27:4238-47.
81. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50.
82. Barh D, Parida S, Parida BP, Viswanathan G. Let-7, MIR-125, MIR-205, and MIR-296 are prospective therapeutic agents in breast cancer molecular medicine. Gene Ther Mol Biol 2008;12:189-206.
83. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30.
84. Peng Y, Laser J, Shi G, et al. Antiproliferative effects by let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 2008;6:663-73.
85. Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008;13:1215-22.
86. He YJ, Guo L, D ZH. Let-7 and MIR-24 in UVB-induced apoptosis [Chinese]. Zhonghua Fang She Yi Xue Yu Fang Hu Za Zhi 2009;29:234-6.
87. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
88. Shell S, Park SM, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 2007;104:11400-5.
89. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007;101:59-68.
90. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008;7:759-64.
91. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-41.
92. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAS in vivo with "antagomirs." Nature 2005;438:685-9.
93. Krutzfeldt J, Kuwajima S, Braich R, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 2007;35:2885-92.
94. Valoczi A, Hornyik C, Varga N, Burgyan J, Kauppinen S, Havelda Z. Sensitive and specific detection of microRNAS by northern blot analysis using lna-modified oligonucleotide probes. Nucleic Acids Res 2004;32:175.
95. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 2006;34:2294-304.
96. Esau C, Davis S, Murray SF, et al. MIR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
97. Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006;372:137-41.
98. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOS): ammunition to target miRNAS implicated in human disease? Gene Ther 2006;13:496-502.
99. Esau CC, Monia BP. Therapeutic potential for microRNAS. Adv Drug Deliv Rev 2007;59:101-14.
100. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAS in mammalian cells. Science 2002;296:550-3.
101. Miyagishi M, Taira K. U6 promoter-driven siRNAS with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002;20:497-500.
102. Soifer HS, Rossi JJ, Saetrom P. microRNAS in disease and potential therapeutic applications. Mol Ther 2007;15:2070-9.
103. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucl Acids Res 2004;32:1154-8.
104. Chung KH, Hart CC, Al-Bassam S, et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on Bic/MIR-155. Nucl Acids Res 2006;34:e53.
105. Zeng Y, Cai X, Cullen BR. Use of RNA polymerase II to transcribe artificial microRNAS. Methods Enzymol 2005;392:371-80.
106. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAS can inhibit the expression of cognate mRNAS when expressed in human cells. Mol Cell 2002;9:1327-33.
107. Zhou H, Xia XG, Xu Z. An RNA polymerase ii construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucl Acids Res 2005;33:e62.
108. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2005;102:13212-17.
109. Chen S, Ni M, Yu B, Lv T, Lu M, Gong F. Construction and identification of a human liver specific microRNA eukaryotic expression vector. Cell Mol Immunol 2007;4:473-7.
110. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic SIRNAS. Nat Biotechnol 2007;25:1149-57.